ARE vs. MRNA, BXP, CUZ, KRC, O, PLD, REXR, VICI, WELL, and DLR
Should you be buying Alexandria Real Estate Equities stock or one of its competitors? The main competitors of Alexandria Real Estate Equities include Moderna (MRNA), BXP (BXP), Cousins Properties (CUZ), Kilroy Realty (KRC), Realty Income (O), Prologis (PLD), Rexford Industrial Realty (REXR), VICI Properties (VICI), Welltower (WELL), and Digital Realty Trust (DLR).
Alexandria Real Estate Equities vs. Its Competitors
Alexandria Real Estate Equities (NYSE:ARE) and Moderna (NASDAQ:MRNA) are related large-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
In the previous week, Alexandria Real Estate Equities had 11 more articles in the media than Moderna. MarketBeat recorded 22 mentions for Alexandria Real Estate Equities and 11 mentions for Moderna. Alexandria Real Estate Equities' average media sentiment score of 0.95 beat Moderna's score of 0.59 indicating that Alexandria Real Estate Equities is being referred to more favorably in the media.
Alexandria Real Estate Equities presently has a consensus price target of $96.47, indicating a potential upside of 22.71%. Moderna has a consensus price target of $41.81, indicating a potential upside of 54.01%. Given Moderna's higher possible upside, analysts plainly believe Moderna is more favorable than Alexandria Real Estate Equities.
Alexandria Real Estate Equities has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Moderna has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.
Alexandria Real Estate Equities has higher earnings, but lower revenue than Moderna. Alexandria Real Estate Equities is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
96.5% of Alexandria Real Estate Equities shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.1% of Alexandria Real Estate Equities shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Alexandria Real Estate Equities has a net margin of -0.33% compared to Moderna's net margin of -94.31%. Alexandria Real Estate Equities' return on equity of -0.05% beat Moderna's return on equity.
Summary
Alexandria Real Estate Equities beats Moderna on 11 of the 17 factors compared between the two stocks.
Get Alexandria Real Estate Equities News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alexandria Real Estate Equities Competitors List
Related Companies and Tools
This page (NYSE:ARE) was last updated on 10/7/2025 by MarketBeat.com Staff
